Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Production of a biosimilar version of aflibercept to improve VEGF blocker cytotoxicity on endothelial cells

Published:2023-06-28 Issue:3 Volume:41 Page:140-151
ISSN:0897-7194
Container-title:Growth Factors
language:en
Short-container-title:Growth Factors

Author:

Ramezani Amin¹²^ORCID,Zareinejad Mohammadrasul²^ORCID,Mahmoudi Maymand Elham²^ORCID,Kaviani Elina¹²^ORCID,Ghaderi Abbas²^ORCID

Affiliation:

1. Department of Medical Biotechnology, School of Advanced Medical Sciences and Technologies, Shiraz University of Medical Sciences, Shiraz, Iran

2. School of Medicine, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran

Funder

National Institute for Medical Research Development

Publisher

Informa UK Limited

Subject

Cell Biology,Clinical Biochemistry,Endocrinology

Link

https://www.tandfonline.com/doi/pdf/10.1080/08977194.2023.2227271

Reference45 articles.

1. VEGF in Signaling and Disease: Beyond Discovery and Development

2. Phase I Dose-Escalation and Pharmacokinetic Study of Intravenous Aflibercept in Combination with Docetaxel, Cisplatin, and 5-Fluorouracil in Patients with Advanced Solid Malignancies

3. Sorafenib in the treatment of advanced hepatocellular carcinoma

4. Vascular Endothelial Growth Factor Trap-Eye for Macular Edema Secondary to Central Retinal Vein Occlusion

5. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured fab in complex with antigen 1 1Edited by I. A. Wilson

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP